Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
Open Access
- 1 January 2023
- journal article
- research article
- Published by XMLink in Journal of Breast Cancer
- Vol. 26 (5) , 519-523
Abstract
De Weger VA, et al. J Breast Cancer. 2023 Aug;26:e38. https://doi.org/10.4048/jbc.2023.26.e38Keywords
This publication has 7 references indexed in Scilit:
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancerESMO Open, 2022
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesESMO Open, 2022
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerNew England Journal of Medicine, 2022
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and managementCancer Treatment Reviews, 2022
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug ConjugatesJAMA Oncology, 2021
- Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2‐targeting Ab–drug conjugate, in monkeysCancer Science, 2020
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerNew England Journal of Medicine, 2020